Bioethics, COVID-19 and Pharmaceutical Industry

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Bioethics

COVID-19

Pharmaceutical Industry

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

Bill of Health

SEPTEMBER 28, 2023

By Nikhil Chaudhry and Reshma Ramachandran Earlier this month, the Department of Health and Human Services announced that it had successfully included a reasonable pricing provision in a $326M investment contract with Regeneron for development of a next generation monoclonal antibody therapy for COVID-19. pharmaceutical market.

COVID-19

COVID-19 COVID-19 Vaccine Pharmaceutical Industry Governance

The Remarkable Rise of Pharma’s Reputation in the Pandemic

Health Populi

FEBRUARY 22, 2021

The reputation of the pharmaceutical industry gained a “whopping” 30 points between January 2020 and February 2021, based on the latest Harris Poll in their research into industries’ reputations. consumers trusted the biotech health industry segment compared with the pharmaceutical segment.

COVID-19

COVID-19 COVID-19 Vaccine Pharmaceutical Industry Public Health

Health Care Compliance Brief

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

The Remarkable Rise of Pharma’s Reputation in the Pandemic

Stay Connected